Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Additional Information (Details)

v3.23.1
Fair Value Measurements - Additional Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Estimated fair value of equity securities $ 25,028,000   $ 32,020,000
Unrealized (loss) gain on equity securities (6,992,000) $ 563,000  
Vaxcyte, Inc. | Vaxcyte Common Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Estimated fair value of equity securities 25,000,000.0   32,000,000.0
Unrealized (loss) gain on equity securities $ (7,000,000.0)   $ 600,000
Vaxcyte, Inc. | Equity Securities | Vaxcyte Common Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Number of shares held 667,780   667,780
Fair Value Measurements Recurring      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Securities held $ 275,125,000   $ 330,430,000
Fair Value Measurements Recurring | Level 3      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Securities held $ 0   $ 0